## Amendment to the Specification:

Please replace paragraph [0014] with the following amended paragraph:

[0014] The synthetic peptides and analogs thereof according to the invention may be selected from the group consisting of peptides having the sequences I to V herein, wherein:

- (i) the peptide of sequence I has the formula:  $T G Y Y X_1 X_2 X_3 X_4 X_5 Q S P E K S L E W I G (SEQ ID NO:1)$  [I] wherein  $X_1$  is Met, Ala or Val;  $X_2$  is Gln, Asp, Glu or Arg;  $X_3$  is Trp or Ala;  $X_4$  is Val or Ser; and  $X_5$  is Lys, Glu or Ala;
- (ii) the peptide of sequence II has the formula: E I N P S T G G  $X_6$   $X_7$   $X_8$   $X_9$   $X_{10}$   $X_{11}$   $X_{12}$  K A K A T (SEQ ID NO:2) [II] wherein  $X_6$  and  $X_7$  are each Thr, Val or Ala;  $X_8$  is Tyr or Phe;  $X_9$  is Asn or Asp;  $X_{10}$  is Gln or Glu;  $X_{11}$  is Lys or Glu, and  $X_{12}$  is Phe or Tyr;
- (iii) the peptide of sequence III has the formula: Y Y C A R  $X_{13}$   $X_{14}$   $X_{15}$   $X_{16}$  P Y A  $X_{17}$   $X_{18}$  Y W G Q G S (SEQ ID NO:3) [III]

wherein  $X_{13}$  is Phe, Thr or Gly;  $X_{14}$  is Leu, Ala or Ser;  $X_{15}$  is Trp or Ala;  $X_{16}$  is Glu or Lys;  $X_{17}$  is Met or Ala, and  $X_{18}$  is Asp, Lys or Ser;

(iv) the peptide of sequence IV has the formula: G Y N  $X_{19}$   $X_{20}$   $X_{21}$   $X_{22}$   $X_{23}$   $X_{24}$  S H G  $X_{25}$   $X_{26}$  L E W I G (SEQ ID NO:4)

[IV]

wherein  $X_{19}$  is Met or Ala;  $X_{20}$  is Asn, Asp or Arg;  $X_{21}$  is Trp or Ala;  $X_{22}$  is Val or Ser;  $X_{23}$  is Lys or Glu;  $X_{24}$  is Gln or Ala;  $X_{25}$  is Lys or Glu, and  $X_{26}$  is Ser or Ala; and

(v) the peptide of sequence V has the formula:

Y Y C A R  $X_{27}$   $X_{28}$   $X_{29}$  Y G  $X_{30}$   $X_{31}$   $X_{32}$  G Q G T L (SEQ ID NO:5) [V] wherein  $X_{27}$  is Ser or Phe;  $X_{28}$  is Gly or Ala;  $X_{29}$  is Arg, Ala or Glu;  $X_{30}$  is Asn or Asp;  $X_{31}$  is Tyr or Phe, and  $X_{32}$  is Trp, His or Ala.

Please replace paragraph [0015] with the following amended paragraph:

[0015] In preferred embodiments, peptides I to V have the sequences Ia-Va herein:

Т	G	Y	Y	M	Q	M	V	K	Q	S	Ρ	Ε	K	S	L	Ε	M	Ι	G	(SEÇ	2	ID	N	0:6	<b>5)</b>	_		(Ia	L)
Ε	Ι	N	Р	S	Т	G	G	Т	Т	Y	N	Q	K	F	K	Α	K	A	Т	(SEÇ	2	ID	N	0:7	7)	_		(IIa	L)
Y	Y	С	Α	R	F	L	M	Ε	Р	Y	Α	M	D	Y	M	G	Q	G	S	(SEÇ	2	ID	N	0:8	3)	_	( ]	IIIa	L )
G	Y	N	Μ	Ν	W	V	K	Q	S	Н	G	K	S	L	E	W	I	G	( 5	SEQ ]	ΙD	N	<u>:</u>	9)	_			(IVa	L )
Y	Y	С	Α	R	S	G	R	Y	G	N	Y	M	G	Q	G	_T	L	( 5	SEÇ	Q ID	N	0:	10	)				(Va	L)

Please replace paragraph [0037] with the following amended paragraph:

[0037] Examples of peptides and analogs thereof are as follows:

(i) Peptide la of the formula:

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

TGYYMQWVKQ S P E K S L E W I G

(SEQ ID NO:6) (Ia)

and substitution analogs thereof in which Met at position 5 is substituted by either Ala or Val, Gln at position 6 is substituted by either Asp, Glu or Arg; Trp at position 7 is substituted by Ala; Val at position 8 by Ser; and Lys at position 9 is substituted by either Glu or Ala; and deletion analogs thereof in which up to 5 amino acid residues are deleted from the C-terminal of peptide Ia.

(ii) Peptide IIa of the formula:

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

EINPSTGGTT Y N Q K F K A K A T

(SEQ ID NO:7) (IIa)

and substitution analogs thereof in which Thr in positions 9 and 10 are each substituted by either Val or Ala; Tyr at position 11 is substituted by Phe; Asn at position 12 is substituted by Asp; Gln at position 13 by Glu; Lys at position 14 by Glu; and Phe at position 15 by Tyr, and deletion analogs thereof in which up to 5 amino acid residues are deleted from the C-terminal of peptide IIa.

(iii) Peptide IIIa of the formula:

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

YYCARFLWEP Y A M D Y W G Q G S

(SEQ ID NO:8) (IIIa)

and substitution analogs thereof in which Phe at position 6 is substituted by either Thr or Gly; Leu at position 7 is substituted by either Ala or Ser; Trp at position 8 is substituted by Ala; Glu at position 9 is substituted by Lys; Met at position 13 by Ala; and Asp at position 14 by either Lys or Ser; and deletion analogs thereof in which up to 5 amino acid residues are deleted from the C-terminal of peptide IIIa.

(iv) Peptide IVa of the formula:

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

GYNMNWVKQS H G K S L E W I G

(SEQ ID NO:9) (IVa)

and substitution analogs thereof in which Met at position 4 is substituted by Ala; Asn at position 5 is substituted by either Asp or Arg; Trp at position 6 is substituted by Ala; Val at position 7 by Ser; Lys at position 8 by Glu; Gln at position 9 by Ala; Lys at position 13 by Glu; and Ser at position 14 by Ala; and deletion analogs thereof in which up to 5 amino acid residues are deleted from the C-terminal of peptide IVa.

(v) Peptide Va of the formula:

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

YYCARSGRYG N Y W G Q <u>G</u>T L

(SEQ ID NO:10) (Va)

and substitution analogs thereof in which Ser at position 6 is substituted by Phe; Gly at position 7 is substituted by Ala; Arg at position 8 is substituted by either Ala or Glu; Asn at position 11 is substituted by Asp; Tyr at position 12 by Phe; and Trp at position 13 by either His or Ala; and deletion analogs thereof in which up to 5 amino acid residues are deleted from the C-terminal of peptide Va.

- 6 -